Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Sustained disease control in transplant-ineligible patients: the role of continuous therapy.

Palumbo A, Niesvizky R.

Leuk Res. 2012 Nov;36 Suppl 1:S19-26. doi: 10.1016/S0145-2126(12)70005-X.

2.

Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma.

Moreau P, Giralt SA.

Leuk Res. 2012 Nov;36 Suppl 1:S13-8. doi: 10.1016/S0145-2126(12)70004-8. Review.

PMID:
23176719
3.

Incorporating novel agents in the management of elderly myeloma patients.

Guglielmelli T, Palumbo A.

Curr Hematol Malig Rep. 2013 Dec;8(4):261-9. Review.

PMID:
24078350
4.

Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.

Kim HJ, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL, Chung JS, Kim K, Suh C, Won JH, Kim JS, Park JS, Kang HJ, Seong CM, Kim CS, Lee SJ, Lee JH.

Ann Hematol. 2012 Feb;91(2):249-56. doi: 10.1007/s00277-011-1298-9. Epub 2011 Jul 26.

PMID:
21789621
5.

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.

Palumbo A, Attal M, Roussel M.

Clin Cancer Res. 2011 Mar 15;17(6):1253-63. doi: 10.1158/1078-0432.CCR-10-1925. Review.

6.

[Treatment of transplant-ineligible patients with multiple myeloma].

Kizaki M.

Nihon Rinsho. 2015 Jan;73(1):95-101. Japanese.

PMID:
25626312
7.

Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?

Ludwig H, Sonneveld P.

Leuk Res. 2012 Nov;36 Suppl 1:S27-34. doi: 10.1016/S0145-2126(12)70006-1. Review.

PMID:
23176721
8.

Maintenance therapy for multiple myeloma.

McCarthy PL, Palumbo A.

Hematol Oncol Clin North Am. 2014 Oct;28(5):839-59. doi: 10.1016/j.hoc.2014.06.006. Epub 2014 Jul 22. Review.

PMID:
25212886
9.

Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.

Steurer M, Spizzo G, Mitterer M, Gastl G.

Onkologie. 2004 Apr;27(2):150-4.

PMID:
15138347
10.

Evolving paradigms in the treatment of newly diagnosed multiple myeloma.

Larocca A, Palumbo A.

J Natl Compr Canc Netw. 2011 Oct;9(10):1186-96. Review.

PMID:
21975915
11.

Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.

Vogl DT, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Perl A, Loren AW, Goldstein SC, Nasta SD, Andreadis C, Mangan PA, Hummel K, Siegel DL, Glatstein E, Stadtmauer EA.

Am J Hematol. 2007 Dec;82(12):1071-5.

12.

The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.

Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Redman KC, McKenney M, Warren D, Noonan K, Lunde L, Doss D, Colson K, Hideshima T, Mitsiades C, Munshi NC, Anderson KC.

Eur J Haematol. 2012 May;88(5):446-9. doi: 10.1111/j.1600-0609.2012.01765.x. Epub 2012 Mar 7.

PMID:
22300348
13.

Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.

Lonial S, Cavenagh J.

Br J Haematol. 2009 Jun;145(6):681-708. doi: 10.1111/j.1365-2141.2009.07649.x. Epub 2009 Mar 17. Review.

PMID:
19344388
14.

Treatment of multiple myeloma in the targeted therapy era.

Saad AA, Sharma M, Higa GM.

Ann Pharmacother. 2009 Feb;43(2):329-38. doi: 10.1345/aph.1L428. Epub 2009 Feb 3. Review.

PMID:
19193585
15.
16.

Continuous treatment in multiple myeloma: the future?

Vande Broek I, Jacobs P.

Transfus Apher Sci. 2013 Oct;49(2):147-50. doi: 10.1016/j.transci.2013.07.017. Epub 2013 Sep 24. Review.

PMID:
24074557
17.

[New concept of the treatment in elderly patients with multiple myeloma].

Bila J, Gotić M, Mihaljević B.

Srp Arh Celok Lek. 2011 Dec;139 Suppl 2:110-5. Serbian.

18.

New generation pharmacotherapy in elderly multiple myeloma patients.

Ataergin SA, Kindwall-Keller T, Berger NA, Lazarus HM.

Expert Opin Pharmacother. 2009 Jan;10(1):81-98. doi: 10.1517/14656560802611808 . Review.

PMID:
19236183
19.

(Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.

Wang A, Duan Q, Liu X, Ding K, Han Y, Zhu W, Cai X, Wu J, Sun Z.

Ann Hematol. 2012 Nov;91(11):1779-84. doi: 10.1007/s00277-012-1520-4. Epub 2012 Jul 7.

PMID:
22773209
20.

Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies.

Morgan G.

Blood Rev. 2010 Nov;24 Suppl 1:S27-32. doi: 10.1016/S0268-960X(10)70006-0.

PMID:
21126634

Supplemental Content

Support Center